332 results
8-K
EX-99.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown … approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business
8-K
EX-10.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
between the Executive and the Company or any of its Affiliates. Except when such acts constituting Cause which, by their nature, cannot reasonably … information of a sensitive, confidential or proprietary nature respecting the business and activities of any member of the Company Group or any
8-K
EX-10.3
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
of CervoMed’s Chief Executive Officer, and shall specify the nature of the work and the expected number of hours to be worked.
5. Tanner … to further the purposes of the preceding paragraph. Tanner hereby waives and quitclaims to the CervoMed any and all claims of any nature whatsoever which
8-K
EX-99.1
CRVO
CervoMed Inc
15 May 24
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5:06pm
to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known … approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement
8-K
EX-99.1
961hhlx nclp
5 Apr 24
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-10.1
kn2pn92y9z7
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-99.1
bc6brvn3h5g 4t2b
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-4.2
0z88mxbm1m4x0y 8sclf
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-99.1
n7a3i1aob5cg8
5 Mar 24
Regulation FD Disclosure
8:51am
8-K
EX-99.1
zzs97crkrkp0r1dl8mw
7 Feb 24
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
4:06pm
8-K
EX-10.3
mi4d4kp56kx
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.2
d1l692 l98o9yt72
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
y9y94d8uhl48ru
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
e54c8f8 7kr07ukd1
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm